| P2093 | author name string | Xu Han | |
| | Lina Xu | |
| | Yan Qi | |
| | Jinyong Peng | |
| | Lianhong Yin | |
| | Xufeng Tao | |
| | Lisha Zhao | |
| P2860 | cites work | Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity | Q26744675 |
| | The role of sirtuins in cardiac disease | Q27693274 |
| | Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity | Q29614981 |
| | Cardiomyocyte autophagy and cancer chemotherapy | Q33573823 |
| | Mitofusin 1 is negatively regulated by microRNA 140 in cardiomyocyte apoptosis | Q33602502 |
| | Animal research: reporting in vivo experiments: the ARRIVE guidelines | Q34116755 |
| | Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage | Q34375948 |
| | MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: expression and bioinformatic analysis. | Q34445757 |
| | Early oxidative damage induced by doxorubicin: Source of production, protection by GKT137831 and effect on Ca(2+) transporters in HL-1 cardiomyocytes. | Q34515261 |
| | MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity | Q35274471 |
| | MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction | Q35763090 |
| | Drug-induced mitochondrial dysfunction and cardiotoxicity | Q36339445 |
| | Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging | Q36451899 |
| | Doxorubicin in experimental and clinical heart failure | Q36562427 |
| | Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. | Q36902292 |
| | Emerging role of hydrogen sulfide-microRNA crosstalk in cardiovascular diseases | Q36902427 |
| | Myricitrin Protects against Doxorubicin-Induced Cardiotoxicity by Counteracting Oxidative Stress and Inhibiting Mitochondrial Apoptosis via ERK/P53 Pathway. | Q37290281 |
| | Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. | Q37896107 |
| | Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. | Q38089704 |
| | Emerging role of microRNAs in cardiovascular diseases. | Q38187516 |
| | Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. | Q38431346 |
| | Systems biology approaches to adverse drug effects: the example of cardio-oncology | Q38606067 |
| | Breast cancer therapy-associated cardiovascular disease | Q38645182 |
| | miRNAs as potential therapeutic targets and diagnostic biomarkers for cardiovascular disease with a particular focus on WO2010091204. | Q38669417 |
| | New signal transduction paradigms in anthracycline-induced cardiotoxicity. | Q38717463 |
| | MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension | Q38757844 |
| | Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. | Q38876257 |
| | Autophagic dysregulation in doxorubicin cardiomyopathy. | Q39096944 |
| | Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats | Q39870539 |
| | Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities | Q39972544 |
| | MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation | Q40036365 |
| | Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. | Q40094247 |
| | Quercetin improves postischemic recovery of heart function in doxorubicin-treated rats and prevents doxorubicin-induced matrix metalloproteinase-2 activation and apoptosis induction. | Q40457739 |
| | 7-deacetylgedunin suppresses inflammatory responses through activation of Keap1/Nrf2/HO-1 signaling | Q41549751 |
| | The Role of the Nrf2/ARE Antioxidant System in Preventing Cardiovascular Diseases | Q42005885 |
| | Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. | Q42332476 |
| | Experimental design and analysis and their reporting: new guidance for publication in BJP. | Q42356330 |
| | Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats. | Q43166156 |
| | Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia | Q46443830 |
| | Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by activating Nrf2. | Q46729636 |
| | CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1. | Q47603462 |
| | Corrigendum to "Crocin protects against doxorubicin-induced myocardial toxicity in rats through down-regulation of inflammatory and apoptic pathways" [Chemico-Biol. Interact. 247 (2016) 39-48]. | Q53766690 |
| | Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. | Q53999100 |
| | The Emerging Role of Small Non-coding RNAs in the Failing Heart: Big Hopes for Small Molecules | Q59192100 |
| | The role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging | Q84001359 |
| | Circulating microRNAs as Biomarkers in Cardiovascular Diseases | Q86809686 |
| | SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy | Q87014417 |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 284-296 | |
| P577 | publication date | 2017-12-29 | |
| P1433 | published in | Redox Biology | Q27724751 |
| P1476 | title | MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. | |
| P478 | volume | 15 | |